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Background: Although several meta-analyses showed the positive effects of follow-up on the prognosis of colon
cancer (CC), international guidelines are not in accordance on appropriate tests and their time frequency to
optimize surveillance. Furthermore, stratified strategies based upon risk grading have not been implemented. This
approach may be useful to rationalize resources.
Methods: From 2006, all patients operated for an early stage CC (I, IIA, IIB) according to the 7th edition of the
AJCC-2010 classification entered in a prospective surveillance program in accordance to our local guidelines.
Patients who underwent surgical resection after 2009 have been excluded to guarantee at least a 5-year follow-up.
Classic histopathologic prognostic factors such as grade, T and N status, lymphatic and vascular invasion were
assessed. Moreover, tumor budding and tumor-to-stroma proportion were evaluated.
Results: We had complete records of 196 patients. Distribution was as follows: 65 (33.2 %) in stage I, 122 (62.2 %) in
stage IIA, and 9 (4.6 %) in stage IIB. Eleven patients (5.6 %) had a disease recurrence (local or distant). The median
recurrence time was 20 months (range 6–48). Nine patients (82 %) had recurrence with 24 months, and 91 % were
asymptomatic and detected by ultrasound or CT scan. According to the log-rank test, the risk factors with
significant effect on the disease-free survival (DFS) were the number of lymph nodes <12 (p = 0.027) and the
vascular invasion (p = 0.021), while for the overall (OS), only the vascular invasion was significant (p = 0.043). By the
univariate and multivariate analyses, DSF was significantly lower in patients with less than 12 nodes removed, with
vascular invasion, and with left of double cancer. OS was negatively affected only by vascular invasion despite the
hazard ratios were similar to DSF. Stage IIB was associated with a threefold-increased risk of reduced OS and DSF.
Conclusions: Stages I and IIA appear to behave similarly and should be considered as true early stages. The
detection of fibrosis and budding do not seem to add valuable information for prognosis. In early CC stages, the
surveillance program should be maximized within the first two years.
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The prognosis of colon cancer (CC) has improved over
the years due to the earlier detection of the disease and
improved surgical techniques and more effective
chemotherapy.
In the management of early stages of CC, surgery
alone remains the best treatment option. Despite the* Correspondence: luca.gianotti@unimib.it
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recurrence and appearance of metachronous metastases
exists, and it is directly correlated with some well known
risk factors such as occlusion or perforation at presenta-
tion, TNM classification, vascular and lymphatic inva-
sion, number of nodes retrieved, tumor grading, KRAS,
BRAF mutation, and microsatellite instability [1–5]. Re-
cently, other histopathologic features of CC such as
tumor budding [6–8] and the presence of fibrosis [9, 10]
have been recognized as important negative predictive
factors. However, the prognostic performance of theseticle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
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stages.
Surveillance remains a cornerstone approach to detect
recurrence at an early stage [11, 12] and consequently to
plan further therapeutic strategies. Although several
meta-analyses have been performed on the positive ef-
fects of the follow-up on CC prognosis [13, 14], inter-
national guidelines are not in accordance on appropriate
tests and their time frequency to optimize surveillance
[15–18]. Furthermore, stratified strategies based upon
risk scaling have not been implemented. This approach
may be useful to rationalize resources.
The aims of this study were to identify predictors of
recurrent disease and long-term survival among sub-
jects operated for early stages (I, IIA, IIB) of CC defined
according to the latest edition of the American Joint
Committee on Cancer (AJCC) [19] and to determine
potential recommendations for a optimize follow-up
protocol.
Methods
Since 2006, we prospectively recorded in an electronic
database all the clinical and pathological data, and the
office visits of all patients operated for CC at the Depart-
ment of Surgery of the Milano-Bicocca University-San
Gerardo Hospital.
All patients entered in a surveillance program in ac-
cordance to our local guidelines (Table 1). All patients
underwent contrast-enhanced abdominal ultrasound. In
cases of unclear results of CEUS imaging, a contrast-
enhanced CT scan was done.
From this database, we retrospectively selected pa-
tients with a potentially curative resection and an early
stage disease (I, IIA, IIB) according to the 7th edition of
the AJCC-2010 classification [19] and operated between
2006 and 2009. We defined a radical resection (R0)
when the resection margins were ≥5 cm, and circumfer-
ential margins were not involved. Patients who under-
went surgical resection after 2009 have been excluded to














60 X XAll cases have been reviewed by two GI pathologists
(GB and NZ) at double-headed microscope to confirm
the following histopathologic prognostic factors: grade,
T and N status, lymphatic and vascular invasion. Tumor
budding (isolated single cancer cells or cluster composed
of fewer than five neoplastic cells) has been evaluated in
each tumor as described by Ueno et al. [6, 7]; fields with
most prominent budding at the tumor invasive margin
were selected and a count of the foci of budding was
made with a ×20 objective. Tumor budding was consid-
ered positive when bud count was higher than 9.
Tumor-to-stroma proportion has been evaluated apply-
ing Huijbers et al. criteria [9]. The stroma percentage
has been estimated at the most invasive area of each
tumor at ×10. Each case has been given a tenfold scoring
percentage and further grouped into the high-stroma
(>50 %) or low-stroma (≤50 %) category for statistical
analysis.
Statistics
Descriptive statistics of the risk factors considered were
computed separately for the patients with and without
recurrent disease. Two end-points were considered:
disease-free survival (DFS), defined as the time elapsed
from the intervention to relapse or death in absence of
relapse or end of the follow-up, and overall survival
(OS), defined as the time elapsed from the intervention
to death by any cause or end of the follow-up. The
Kaplan-Meier survival curves were estimated for the two
end-points and for each risk factor, and were compared
using the log-rank test. Finally, the effect of the risk fac-
tors on the two end-points was evaluated with both uni-
variate and multivariate regression analyses, using the
Cox model. All p values <0.05 were considered signifi-
cant. The R software version 3.0.2 was used for statistical
analyses.
Results
In the study period, a total number of 567 patients were
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in stage III; 105 in stage IV. Two hundred and thirty-
three subjects with stage I, IIA, or IIB were selected.
Thirty-four patients (14.6 %) were excluded for incom-
plete or lost at follow-up and three patients for incom-
plete data for pathology examination. A final population
of 196 patients with complete records was distributed as
follows: 65 (33.2 %) in stage I, 122 (62.2 %) in stage IIA,
and 9 (4.6 %) in stage IIB.
Eleven patients (5.6 %) had a disease recurrence (local
or distant). The characteristics of the overall population
and of the patients with and without recurrence are de-
scribed in detail in Table 2. No significant differences
were observed when patients with and without recur-
rence were compared with the exception of cancer site.
Subjects with tumor of the left colon and multiple can-
cer location were at significant higher risk of recurrence.
We observed a trend toward a significant increase of risk
for patients with less than 12 nodes retrieved, presence
of vascular and lymphatic invasion and high presence of
fibrosis.
Table 3 shows the characteristics of the patients with
recurrence, the site and timing of recurrence and the
diagnostic tools used to prove it. Adjuvant chemother-
apy was prescribed in 2 cases: one for cancer perforation
and one for the small number of lymph nodes removed
(n = 5) and massive lymphatic/vascular invasion. The
mean recurrence time was 20 months from surgery
(range of 6–48 months). In nine out of eleven patients
(81.8 %), recurrence was within 24 months, and in all
cases but one (90.9 %), recurrence was asymptomatic
and detected by ultrasound or CT scan. Two patients
had local recurrence, three pulmonary, one local and
pulmonary, and five hepatic metastases. The Kaplan-
Meier estimates (95 % CI) of the DFS and OS on the
whole sample at 5 years after diagnosis were 0.878
(0.829–0.929) and 0.905 (0.860–0.953), respectively
(Fig. 1). According to the log-rank test, the risk factors
with a statistically significant effect on the DFS were the
number of lymph nodes <12 (p = 0.027) and the vascular
invasion (p = 0.021), while for the OS only the vascular
invasion was significant (p = 0.043). These results are
shown graphically by the Kaplan-Meier curves of Fig. 2
(DFS) and Fig. 3 (OS).
By the univariate analysis, DSF was significantly lower
in patients with less than 12 nodes removed, with vascu-
lar invasion, and with left or double cancer. From a stat-
istical point of view, OS was negatively affected only by
vascular invasion despite the hazard ratios being similar
to DSF. Stage IIB was associated with a threefold-
increased risk of reduced OS and DSF, but the data
might have generated bias for the small number of pa-
tients. By the multivariate analysis, the risk factors for
decreased OS and DSF confirmed the results of theunivariate analysis but only left and double cancer
reached statistical significance (Table 4).
Discussion
The main potential benefit of implementing follow-up
programs is the early detection and subsequent treat-
ment of disease relapse particularly when recurrence is
asymptomatic [20]. The major challenge for any health
care provider is to find a reasonable balance between op-
timal time intervals of surveillance visits and radiological
imaging and health care resources used to provide these
examinations. If on one side, patients derive a sense of
well-being and reassurance with regular follow-up, on
the other a strict surveillance may create anxiety prior to
their visit and potential of false positive tests may result
in further concern.
Recently several scientific societies and groups of ex-
perts provided guidelines and recommendations for the
optimal strategies to implement follow-up of colon can-
cer [16, 21, 22]. One of the potential limitations is the
lack of stratification of recurrent risk among different
cancer stages, since the above recommendations are
generically stated for all cancer stages. It is well recog-
nized that early stages of colon cancer have a lower risk
of relapse, and therefore, more accurate strategies for
optimizing and tailoring surveillance protocols might be
proposed. A risk-adapted follow-up in which the inten-
sity varies according to the risk of recurrence might in-
crease the cost-effectiveness by concentrating resources
on patients at high risk. Selective use of intensive follow-
up regimens, excluding patients at low risk for recur-
rence and patients who cannot tolerate further curative
resection while concentrating on subpopulations of pa-
tients at high risk, may increase the utility of such
regimens and thus improve efficacy. Continued im-
provements in risk stratification, disease detection, and
treatment might increase the benefits of postoperative
surveillance.
In this line of thought, we analyzed the overall and
disease-free survival rates of patients with stage I, IIA,
and IIB to evaluate if among these subjects we might
find specific variables useful to identify cohorts with low
or high risk of recurrence in order to split subgroups in
which follow-up may be more of less intensive in term
of time intervals of visits and diagnostic workup.
Our 5-year follow-up data are in accordance with re-
cent large series [23] reporting overall and disease-free
survival rates. Recurrent time and site were also quite
consistent with other reports [21, 24]. In our series,
82 % of the patients were diagnosed with recurrence
within 2 years and in all but one case, relapse was de-
tected by US or CT scan.
By substage analyses, we found that overall and disease-
free survival curves of stage I and IIA were almost
Table 2 Characteristics of the overall population and of patients with or without recurrence
Characteristic Total Recurrence Non recurrence p value
Overall patients 196 11 (5.6) 185 (94.4)
Gender
Male 117 (59.7) 5 (45.5) 112 (60.5) 0.356
Female 79 (40.3) 6 (54.5) 73 (39.5)
Median age (range), years 70 (40–89) 71 (63–81) 70 (40–89) 0.262
ASA score
1 7 (3.6) 0 7 (3.8) 0.661
2 116 (59.2) 7 (63.6) 109 (58.9)
3 66 (33.7) 3 (27.3) 63 (34.1)
4 7 (3.6) 1 (9.1) 6 (3.2)
Tumor site
Right colon 83 (42.3) 2 (18.2) 81 (43.8) 0.009
Trasversum colon 17 (8.7) 0 17 (9.2)
Left colon 94 (48.0) 8 (72.7) 86 (46.5)
>1 location 2 (1.0) 1 (9.1) 1 (0.5)
T
1 10 (5.1) 0 10 (5.4) 0.772
2 56 (28.6) 3 (27.3) 53 (28.6)
3 121 (61.7) 7 (63.6) 114 (61.6)
4a 9 (4.6) 1 (9.1) 8 (4.3)
Stage
1 65 (33.2) 3 (27.3) 62 (33.5) 0.726
2A 122 (62.2) 7 (63.6) 115 (62.2)
2B 9 (4.6) 1 (9.1) 8 (4.3)
Grading
1 15 (7.7) 0 15 (8.1) 0.349
2 166 (84.7) 11 (100) 155 (83.8)
3 15 (7.7) 0 15 (8.1)
Lymph nodes retrieved
> = 12 153 (78.1) 6 (54.5) 147 (79.5) 0.066
<12 43 (21.9) 5 (45.5) 38 (20.5)
Vascular invasion
yes 9 (4.6) 2 (18.2) 7 (3.8) 0.083
no 187 (95.4) 9 (81.8) 178 (96.2)
Lymphatic invasion
yes 32 (16.3) 4 (36.4) 28 (15.1) 0.084
no 164 (83.7) 7 (63.6) 157 (84.9)
Growth
Infiltrative 108 (55.1) 7 (63.6) 101 (54.6) 0.784
Expansive 88 (44.9) 4 (36.4) 84 (45.4)
Lymphocyte infiltration
no 60 (30.6) 6 (54.5) 54 (29.2) 0.301
small 19 (9.7) 1 (9.1) 18 (9.7)
small-moderate 71 (36.2) 2 (18.2) 69 (37.3)
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Table 2 Characteristics of the overall population and of patients with or without recurrence (Continued)
moderate 22 (11.2) 0 22 (11.9)
severe 24 (12.2) 2 (18.2) 22 (11.9)
Setting
elective surgery 180 (91.8) 11 (100) 169 (91.4) 0.605
emergency 16 (8.2) 0 16 (8.6)
Blood transfusions
no 164 (83.7) 10 (90.9) 151 (81.6) 0.707
yes 35 (16.3) 1 (9.1) 34 (18.4)
Fibrosis
10 100 (51.0) 3 (27.3) 97 (52.4) 0.054
20 28 (14.3) 2 (18.2) 26 (14.1)
30 22 (11.2) 2 (18.2) 20 (10.8)
40 12 (6.1) 1 (9.1) 11 (5.9)
50 12 (6.1) 0 12 (6.5)
60 8 (4.1) 0 8 (4.3)
70 11 (5.6) 2 (18.2) 9 (4.9)
80 3 (1.5) 1 (9.1) 2 (1.1)
90 0 0 0
100 0 0 0
Fibrosis grade
High (> = 50 %) 34 (17.3) 3 (27.3) 31 (16.8) 0.408
Low (<50 %) 162 (82.7) 8 (72.7) 154 (83.2)
Budding
High (> = 10 foci) 38 (19.4) 4 (36.4) 34 (18.4) 0.229
Low (<10 foci) 158 (80.6) 7 (63.6) 151 (81.6)
Data are number of patients (%) or median (range) when specified
Table 3 Characteristics of the eleven patients with recurrent disease
Patient Initial stage Adjuvant chemotherapy
after surgery






1 I No Liver No 6 CEUS and CT
2 I No Local and lung No 24 CEUS and CT
3 IIA No Lung No 48 CT
4 IIA No Liver No 18 CEUS and CT
5 IIA Yes Lung No 18 CT
6 IIA + I No Liver No 18 CT
7 IIA No Liver Abdominal pain 42 CEUS and CT
8 IIA Yes Lung No 24 CT
9 IIA No Local No 12 CT
10 I No Local No 12 Colonoscopy
11 IIB No Liver No 12 CT
CEUS contrast-enhanced ultrasound
CT computed tomography
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Fig. 1 Kaplan-Meier curves for overall survival and disease-free survival. Marks at censoring times. Bands are 95 % confidential intervals
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cancer-related mortality. With the intrinsic limitation of
the small number of patients in our series, the present re-
sults confirm that stage IIB should be considered as a sub-
group with poorer prognosis [25].
By analyzing the impact of single risk factors on recur-
rence, we observed that left or double site cancer were
negative prognostic variables. This relationship between
relapse and tumor location is not clear, but it may be re-
lated to tumor biology. One specific aspect of tumor
biology is microsatellite instability (MSI). Multiple stud-
ies [5, 26] found that patients with MSI-positive tumors
have a better overall prognosis and that MSI status is an
independent positive predictor of survival. MSI is pre-
dominantly seen in right-sided colon cancers, and less
than 5 % of left-sided cancers show MSI. Probably, in
the next future, it will be necessary to include routinely
MSI description in pathologic specimens to obtain a
higher prognostic performance.
Several investigators aimed to identify a specific “ideal
minimum” number of nodes to be reported. There has
been great variation between studies in terms of identify-
ing an “ideal minimum” number of nodes to be exam-
ined in stage II cancers, with figures ranging from 6 to
17 nodes [27–29]. An accurate description of node in-
volvement may be particularly important in stage II tu-
mors for a number of reasons. Firstly, the identification
of a specific figure provides an indicator as to where it
can be stated with defined certainty that the risk of
long-term mortality is reduced [28, 29]. Secondly, it pro-
vides an important means of institutional quality control.
Interestingly, the American National Quality Forum has
endorsed a number of 12 nodes as a standard for asses-
sing hospital performance in the surgical management of
colonic tumors [27, 30]. Finally, an ideal minimum num-
ber of nodes may also be used as a “cut-off” value, below
which stage II patients may be offered adjuvant chemo-
therapy [27].In the present reports, the rate of patients with less
than 12 nodes retrieved was 22 %. This figure is in line
with other large series [31, 32], advocating that this is a
common and worldwide problem, since this represents a
negative prognostic factor [3, 33] as also suggested by
our data.
Recently, tumor budding has been reported as one of
the major malignant characteristics of colorectal carcin-
omas. It is defined as the presence of isolated single cells
or small cell clusters (up to four cells) scattered in the
stroma at invasive fronts; this represents feature loss of
both glandular differentiation and cell cohesion that is
crucial for the development of high invasive properties
[6, 34]. Ueno classification divided it into high grade
budding (≥10 foci) or low grade (<10 foci).
Lai et al. [35] reported that, in his experience, tumor
budding is an important prognostic parameter for
cancer-specific outcomes in patients with stage II colo-
rectal cancer. They concluded that tumor budding could
help to identify high-risk patients who might benefit
from adjuvant chemotherapy. Othsuki et al. [36] demon-
strated a significant difference in disease-free survival
using our definition (high grade ≥10 foci, low grade <10
foci). Likely, our negative results were related to the rela-
tive low number of patients or for the inclusion of pa-
tient in stage I, and the exclusion of rectal cancer.
The presence and the degree of fibrosis in the cancer
seems to be another important prognostic negative fac-
tor [37]. Mesker et al. [10] proposed a differentiation into
high percentage (≥50 % of fibrosis) and low percentage
(<50 %). Huijbers et al. [9] in a series of 710 patients
observed a significant decrease in the overall survival
and disease-free survival for the patients with high per-
centage of fibrosis versus patients with a low percentage
of fibrosis (69 vs. 83 % and 58 vs. 77 %, respectively) but
without differentiating the prognostic ability by stage.
Our results suggest that, at least, in early colon cancer
stages, fibrosis is not a key prognostic element.
Fig. 2 Kaplan-Meier curves for disease-free survival stratified for specific risk factors such as budding, fibrosis, staging, number of nodes, vascular
and lymphatic invasion, tumor site, and adjuvant chemotherapy
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Fig. 3 Kaplan-Meier curves for overall survival stratified for specific risk factors such as budding, fibrosis, staging, number of nodes, vascular and
lymphatic invasion, tumor site and adjuvant chemotherapy
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Table 4 Risk factors analyzed by univariate and multivariate (Cox regression models) for disease-free survival (DFS) and overall
survival (OS)
Univariate analysis Multivariate analysis
DFS HR (95 % CI) OS HR (95 % CI) DFS HR (95 % CI) OS HR (95 % CI)
Gender
Female 1 1 1 1
Male 0.59 (0.25–1.40) 0.57 (0.21–1.57) 0.41 (0.16–1.05) 0.41 (0.14–1.25)
Age, years 1.06 (1.01–1.12) 1.09 (1.02–1.16) 1.07 (1.01–1.12) 1.09 (1.02–1.16)
Budding
No 1 1 1 1
Yes 1.72 (0.67–4.44) 1.09 (0.31–3.85) 1.22 (0.35–4.16) 1.06 (0.23–4.87)
Fibrosis
<50 % 1 1 1 1
> = 50 % 1.98 (0.77–5.10) 1.23 (0.35–4.35) 1.21 (0.37–3.94) 1.01 (0.22–4.61)
Stage
1 1 1 1 1
2A 1.11 (0.42–2.93) 0.80 (0.26–2.46) 1.08 (0.35–3.30) 1.13 (0.31–4.13)
2B 2.89 (0.58–14.35) 3.68 (0.71–19.00) 4.07 (0.63–26.08) 5.81 (0.77–43.92)
Lymph nodes retrieved
> = 12 1 1 1 1
<12 2.56 (1.09–6.25) 2.70 (1.03–7.69) 2.13 (0.76–5.88) 2.38 (0.71–8.33)
Vascular invasion
No 1 1 1 1
Yes 3.78 (1.12–12.91) 3.19 (0.72–14.15) 3.43 (0.87–13.58) 2.91 (0.59–14.31)
Lymphatic invasion
No 1 1 1 1
Yes 1.71 (0.63–4.67) 0.83 (0.19–3.69) 0.88 (0.26–2.94) 0.85 (0.09–2.89)
Site
Right or trasversum 1 1 1 1
Left or double 2.69 (1.04–6.93) 2.06 (0.70–6.04) 3.56 (1.24–10.21) 3.34 (0.98–11.84)
Chemotherapy
No 1 1 1 1
Yes 1.12 (0.38–3.34) 0.76 (0.17–3.37) 1.52 (0.39–5.97) 1.37 0.24–7.99)
HR hazard ratio
CI confidential interval
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stated that the use of adjuvant chemotherapy in stage II
CC remains controversial. In general, stage IIA can be
considered low risk while stage IIB deserves adjuvant
treatment. In stage IIA adjuvant treatment may be consid-
ered in the presence of unfavorable prognostic factors: ob-
struction or perforation debut, contiguity infiltration of
neighboring organs, high grading, number of lymph
nodes examined <12 and vascular, perineural or lymph-
atic infiltration [25]. Our policy was to candidate pa-
tients to adjuvant chemotherapy in stage IIB and in
stage IIA only when at least two of the above risk fac-
tors were present. This conservative policy was basedon the recommendations available at the time the study
initiated. In fact, evidence from randomized controlled
trials did not support the use of adjuvant chemother-
apy, even for patients with high-risk stage II colon can-
cer [38] or at most when at least two risk factors were
present [39].
Conclusions
In conclusion, the present results suggest that staging re-
mains of paramount importance in detecting patients at
high risk of recurrence and in assigning a correct prog-
nosis of long-term survival. The number of lymph nodes
retrieved, the presence of vascular invasion, and the left
Gilardoni et al. World Journal of Surgical Oncology  (2015) 13:260 Page 10 of 11or multiple cancer location are negative prognostic fac-
tors and should be take into account for the possibility
of additional therapies. The detection of fibrosis and
budding do not seem to add valuable information for
prognosis. In early colon cancer stages, the surveillance
program should be maximized within the first 2 years.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
EG was responsible for the follow-up program, conceived the study, and
drafted the manuscript. DPB was responsible for database quality and
performed the statistical analysis. SP, ML, MG coordinated the follow-up
strategies, helped to draft the manuscript, and participated to the study
design. NZ and GB performed histopathology and drafted the manuscript.
MT and AB were the coordinators of the colorectal cancer program and
participated in the study design. LG was the study design coordinator, the
principal investigator, and also drafted the manuscript. All authors read
and approved the final manuscript.
Author details
1Department of Surgery and Translational Medicine, Milano-Bicocca
University, San Gerardo Hospital, Monza, Italy. 2Department of Health
Science, Centre of Biostatistics for Clinical Epidemiology, Milano-Bicocca
University, Monza, Italy. 3Unit of Pathology, San Gerardo Hospital, Monza,
Italy. 4Department of Surgery, San Gerardo Hospital (4° piano A), Via
Pergolesi 33, 20052 Monza, Italy.
Received: 25 March 2015 Accepted: 5 August 2015
References
1. Gianotti L, Tamini N, Nespoli L, Rota M, Bolzonaro E, Frego R, et al. A
prospective evaluation of short-term and long-term results from colonic
stenting for palliation or as a bridge to elective operation versus immediate
surgery for large-bowel obstruction. Surg Endosc. 2013;27:832–42.
2. Gunderson LL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN.
Categorization for colon cancer based on national survival outcomes data.
J Clin Oncol. 2010;28:264–71.
3. Vather R, Sammour T, Kahokehr A, Connolly AB, Hill AG. Lymph node
evaluation and long-term survival in Stage II and Stage III colon cancer: a
national study. Ann Surg Oncol. 2009;16(3):585–93.
4. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR,
et al. Prognostic factors in colorectal cancer. College of American
Pathologists Consensus Statement 1999. Arch Pathol Lab Med.
2000;124:979–94.
5. Merok MA, Ahlquist T, Røyrvik EC, Tufteland KF, Hektoen M, Sjo OH, et al.
Microsatellite instability has a positive prognostic impact on stage II
colorectal cancer after complete resection: results from a large, consecutive
Norwegian series. Ann Oncol. 2013;24:1274–82.
6. Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Tumour ‘budding’ as an
index to estimate the potential of aggressiveness in rectal cancer.
Histopathology. 2002;40:127–32.
7. Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K, et al. Risk
factors for an adverse outcome in early invasive colorectal carcinoma.
Gastroenterology. 2004;127:385–94.
8. Prall F, Nizze H, Barten M. Tumor budding as prognostic factor in stage I/II
colorectal carcinoma. Histopathology. 2005;47:17–24.
9. Huijbers A, Tollenaar RA, vPelt GW, Zeestraten EC, Dutton S, McConkey CC,
et al. The proportion of tumor stroma as a strong prognosticator for stage II
and III colon cancer patients: validation in the VICTOR trial. Ann Oncol.
2013;24:179–85.
10. Mesker WE, Junggeburt JM, Szuhai K, de Heer P, Morreau H, Tanke HJ, et al.
The carcinoma-stroma ratio of colon carcinoma is an independent fact of
survival compared to lymph node status and tumor stage. Cell Oncol.
2007;29:387–98.
11. Törnqvist A, Ekelund G, Leandoer L. Early diagnosis of metachronous
colorectal carcinoma. Aust NZJ Surg. 1981;51:442–5.12. Heald RJ, Lockhart-Mummery HE. The lesion of the second cancer of the
large bowel. Br J Surg. 1972;59:16–9.
13. Castells A, Bessa X, Daniels M, Ascaso C, Lacy AM, García-Valdecasas JC, et al.
Value of postoperativen surveillance after radical surgery for colorectal
cancer. Results of a cohort study. Dis Colon Rectum. 1998;41:714–24.
14. Renehan AG, Egger M, Saunders MP, O’Dwyer ST. Impact on survival of
intensive follow-up after curative resection for colorectal cancer: systematic
review and meta-analysis of randomized trials. BMJ. 2002;324(7341):813.
15. Bruinvels D, Stiggelbout A, Kievit J, Van Houwelingen H, Habbema J, Van de
Velde C. Follow-up of patients with colorectal cancer. A meta-analysis. Ann
Surg. 1994;219:174–82.
16. Jefferey M, Hickey B, Hider P. Follow-up strategies for patients treated for
non metastatic colorectal cancer. Cochrane Database Syst Rev. 2007;1,
CD002200.
17. Tjandra J, Chan M. Follow-up after curative resection of colorectal cancer: a
meta-analysis. Dis Colon Rectum. 2007;50:1783–99.
18. Scholefield JH, Steele RJ. Guidelines for follow up after resection of
colorectal cancer. Gut. 2002;51 Suppl 5:V3–5.
19. Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer
staging manual. 7th ed. 2010. revised 2013.
20. Figueredo A, Rumble RB, Maroun J, Earle CC, Cummings B, McLeod R, et al.
Follow-up of patients with curatively resected colorectal cancer: a practice
guideline. BMC Cancer. 2003;3:26–32.
21. Buie WD, Attard JA. Follow up recommendations for colon cancer. Clin
Colon Rectal Surg. 2005;18:232–43.
22. Hammod K, Margolin DA. The role of postoperative surveillance in
colorectal cancer. Clin Colon Rectal Surg. 2007;20:249–54.
23. Hari DM, Leung AM, Lee JH, Sim MS, Vuong B, Chiu CG, et al. AJCC Cancer
Staging Manual 7th edition criteria for colon cancer: do the complex
modifications improve prognostic assessment? J Am Coll Surg.
2013;217:181–90.
24. Tsikitis VL, Malireddy K, Green EA, Christensen B, Whelan R, Hyder J, et al.
Postoperative surveillance recommendations for early stage colon cancer
based on results from the clinical outcomes of surgical therapy trial. J Clin
Oncol. 2009;27:3671–6.
25. Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A. ESMO
Guidelines Working Group. Primary colon cancer: ESMO Clinical Practice
Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol.
2010;21 Suppl 5:v70–7.
26. Arnold CN, Goel A, Blum HE, Boland CR. Molecular pathogenesis of
colorectal cancer. Cancer. 2005;104:2035–47.
27. Chang GJ, Rodriguez-Bigas MA, Skibber JM, Moyer VA. Lymph node
evaluation and survival after curative resection of colon cancer: systematic
review. J Natl Cancer Inst. 2007;99:433–41.
28. Swanson RS, Compton CC, Stewart AK, Bland KI. The prognosis of T3N0
colon cancer is dependent on the number of lymph nodes examined. Ann
Surg Oncol. 2003;10:65–71.
29. Wong JH, Severino R, Honnebier MB, Tom P, Namiki TS. Number of nodes
examined and staging accuracy in colorectal carcinoma. J Clin Oncol.
1999;17:2896–900.
30. National Quality Forum. Specifications of the national voluntary consensus
standards for breast and colon cancer. http://www.qualityforum.org/Publications/
2009/05/National_Voluntary_Consensus_Standards_for_Quality_of_Cancer_
Care.aspx. Accessed 18 Jan 2007.
31. Weiss JM, Pfau PR, O’Connor ES, King J, LoConte N, Kennedy G, et al.
Mortality by stage for right- versus left-sided colon cancer: analysis of
surveillance, epidemiology, and end results—medicare data. J Clin Oncol.
2011;29:4401–9.
32. Dillman RO, Aaron K, Heinemann FS. McClure SEIdentification of 12 or more
lymph nodes in resected colon cancer specimens as an indicator of quality
performance. Cancer. 2009;115:1840–8.
33. Law CH, Wright FC, Rapanos T, Alzahrani M, Hanna SS, Khalifa M, et al.
Impact of lymph node retrieval and pathological ultra-staging on the
prognosis of stage II colon cancer. J Surg Oncol. 2003;84:120–6.
34. Xu CJ, Mikami T, Nakamura T, Tsuruta T, Nakada N, Yanagisawa N, et al.
Tumor budding, myofibroblast proliferation, and fibrosis in obstructing
colon carcinoma: the roles of Hsp47 and basic fibroblast growth factor.
Pathol Res Pract. 2013;209:69–74.
35. Lai YH, Wu LC, Li PS, Wu WH, Yang SB, Xia P, et al. Tumour budding is a
reproducible index for risk stratification of patients with stage II colon
cancer. Colorectal Dis. 2014;16:259–64.
Gilardoni et al. World Journal of Surgical Oncology  (2015) 13:260 Page 11 of 1136. Ohtsuki K, Koyama F, Tamura T, Enomoto Y, Fujii H, Mukogawa T, et al.
Prognostic value of immunohistochemical analysis of tumor budding in
colorectal carcinoma. Anticancer Res. 2008;28:1831–6.
37. Kanazawa H, Mitomi H, Nishiyama Y, Kishimoto I, Fukui N, Nakamura T, et al.
Tumor budding at invasive margins and outcome in colorectal cancer.
Colorectal Dis. 2008;10:41–7.
38. Benson 3rd AB, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn
PJ, et al. American Society of Clinical Oncology recommendations on
adjuvant chemotherapy for stage II colon cancer. J Clin Oncol.
2004;22:3408–19.
39. Gertler R, Rosenberg R, Schuster T, Friess H. Defining a high-risk subgroup
with colon cancer stages I and II for possible adjuvant therapy. Eur J Cancer.
2009;45:2992–9.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
